Hypotension in hemodialysis
Conditions
Interventions
Dialyzers will be changed to the dialyzer, Toraylight NV, having good biocompatibility on patients who need to treatment for hypotension during dialysis.
Polysulfone(without NV) dialyzers will not be
Sponsors
ATHRITE BP Study Group
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Stable hemodialysis patients whose primary disease is diabetic nephropathy. (Patients have the dialysis vintage more than 1 year.) 2) The patients whose age is between 20 and 80 years at the time of enrollment in this study. 3) The patients who are using polysulfone dialyzers (PS, PES, PEPA) excluding NV series and VPS series. 4) The patients who receive treatment for hypotension induced by dialysis more than twice a month.
Exclusion criteria
Exclusion criteria: 1) A patient who is treated with other renal insufficiency therapies, continuous ambulatory peritoneal dialysis and hemodiafiltration, excluding hemodialysis. 2) A patient who is enrolled to other clinical study. 3) Cancer bearing patients. 4) A patient who has anamnestic cardiovascular diseases (heart attack, stroke) in less than 3 months. 5) A patient during infectious disease treatment. 6) A patient who is consider as onset of acute inflammation. 7) A patient who is a pregnant or intends to become a pregnant within one year. 8) A patient who is judged as the inadequate subject of this study by the doctor.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The event number of hypotension during dialysis is observed for 6 months on two groups of NV group and conventional DL group. (NV group; conventional dialyzers are changed to NV. Conventional DL group; conventional dialyzers are used continuously.) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Hemodynamics: Blood pressure at 0 and 240 minutes after the beginning of session, Catecholamine. 2) Dialysis dose: BUN (KT/V), Beta2-MG 3) Physique, electrolyte: BMI,Na,K,Cl,chest x-ray (CTR) 4) Ca, phosphate metabolism: P, Ca, int-PTH 5) Control anemia: Hb, EPO dose, serum ferritin 6) Nutritional status: serume Alb concentration. 7) Inflammatory status: high sensitive CRP, Pentraxin 3 8) Lipid: Total cholesterol, triglyceride, HDL cholesterol, LDL cholesterol 9)Oxidative stress: Homocysteine, Pentosidine 10) Arteriosclerosis index: PWV, ABI | — |
Countries
Japan
Contacts
Public ContactTsuchida Kenji
Kawashima Hospital Division of Nephrology, Endocrinology
Outcome results
None listed